Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
News|Articles|May 2, 2004
- Pharmaceutical Technology-05-02-2004
- Volume 28
- Issue 5
aaiPharma Situation Underscores The Need for Due Diligence
Author(s)Jim Miller
Sponsors who have been lax in performing financial due diligence on their contractors have been given a wake-up call by the recent developments at aaiPharma.
Advertisement
Articles in this issue
over 22 years ago
In The Spotlight-May 2004over 22 years ago
FDA Eyes Manufacturing Innovation to Boost Drug Developmentover 22 years ago
Prepare for Bar Codingover 22 years ago
Excipient Functionalityover 22 years ago
May 2004Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Advertisement
Advertisement